Physician profile
Jill Javahery
NPI 1568647022
$4,178.93
in general payments reported to CMS, 2019-2025
28 companies · $807 in 2025
The $807 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $320 · 2021: $409 · 2022: $545 · 2023: $663 · 2024: $903 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.48 | 2020-2025 | |
| Leo Pharma INC. | $497.18 | 2023-2025 | Adbry |
| Galderma Laboratories, L.P. | $473.76 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Novartis Pharmaceuticals Corporation | $347.28 | 2019-2025 | |
| Janssen Biotech, INC. | $305.14 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $268.63 | 2022-2025 | Opzelura |
| Pfizer INC. | $183.76 | 2019-2025 | |
| Allergan, INC. | $165.12 | 2019-2022 | |
| Genzyme Corporation | $116.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.38 | 2023-2024 | Sotyktu |
| Amgen INC. | $108.57 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $82.55 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $81.16 | 2019-2021 | |
| Almirall LLC | $68.61 | 2019-2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.92 | 2019-2025 | Siliq, Cabtreo, Jublia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $47.59 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $41.38 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $34.83 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $32.19 | 2019 | |
| Epi Health, LLC | $28.65 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $21.91 | 2019 | |
| Genentech USA, INC. | $21.05 | 2023 | Xolair |
| Bioventus LLC | $19.30 | 2022 | |
| Botanix Sb INC | $19.27 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $17.64 | 2019 | |
| Organon LLC | $16.89 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $16.30 | 2019 | |
| Prugen, INC. Pharmaceuticals | $2.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Javahery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.